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Lomustine is a nitrosourea anticancer agent shown to be effective for treatment of childhood medulloblastoma. In silico
substructure searches produced 17 novel nitrosourea agents analogous to lumustine and retaining activity for DNA alkylation and
cytotoxic activity. The mean values for Log P, polar surface area, formula weight, number of oxygens & nitrogens, and rotatable
bonds were 2.524, 62.89 Anstroms2, 232.8, 5, and 2, respectively. All 17 agents have formula weight less than 450 and Log P less
than 5, two criteria preferred for blood-brain barrier penetration. These agents have a polar surface area less than 90 Angstroms2.
Each show zero violations of the Rule of five indicating favorable drug likeness and oral drug activity. Hierarchical cluster analysis
indicated that 16 of the novel agents were highly similar to lomustine, save for agent 12 which bears a hydroxylated branched carbon
substituent. A total of 17 novel anticancer agents were elucidated havingmolecular properties very effective for penetrating through
the BBB and into the central nervous system. This study shows the effectiveness of in silico search and recognition of anticancer
agents that are suitable for the clinical treatment of brain tumors.
1. Introduction
Tumors of the brain and spinal cord are considered the third
most common type of childhood cancers with only leukemia
and lymphoma having greater occurrence. Tumors that occur
in the central nervous system (CNS) can be either primary
(tumors that originate in the CNS) or metastatic (tumors
formed from cancer cells having origins in other parts of
the body). The various types of childhood spinal cord and
brain tumors include the following: astrocytomas, atypical
teratoid tumor, brain stem glioma, CNS embryonal tumor,
CNS germ cell tumor, craniopharyngioma, ependymoma,
medulloblastoma, spinal cord tumors, and supratentorial
primitive neuroectodermal tumors [1].
Themetastases-type tumors are themost common type of
cancer of the CNS and appear to be increasing in incidence
[2]. The pathophysiology of the brain in which metastases
occur is very important for it is the location of the tumor that
can lead clinicians to apply more effective therapies to target
tumor growth [2].
Clinical studies conducted in Korea have shown that
females aremore inclined to CNS tumors (at a ratio of 1.43 : 1)
and with the most common tumor type to be meningioma
(31.2%), followed by glioblastoma (30.7%), and finally malig-
nant primary tumors (19.3%) [3]. For childhood aged cases
(these being less than 19 years of age) the most common
types are germ cell tumors and embryonal-medulloblastoma
[3]. Therapies for younger children having medulloblastoma
include the use of multiagent chemotherapeutic approaches
[4]. For children older than 3 years having nondisseminated
disease and for partially resected high-risk disease, the
standard therapy includes both treatment with radiotherapy
and adjuvant chemotherapy [5].Most therapeutic approaches
have focused on either delaying or eliminating radiother-
apy by the use of increasingly aggressive chemotherapeutic
approaches [6].
The design of novel drugs to treat CNS-located tumors
should be focused on agents having useful antitumor activity
in addition to the capability of crossing the blood-brain
barrier (BBB) [7]. Children of all ages are susceptible to
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the adverse effects of radiation on brain development. Results
suggest that chemotherapy can be used to delay and some-
times obviate the need for radiation therapy in 20% to
40% of children younger than 3 years with nondisseminated
medulloblastoma [8–10]. The appearance of brain metastases
occurs in up to 40% of cancer patients with this incidence
increasing in frequency [11].
Children diagnosed with neuroectodermal tumor of the
cerebella, referred to as medulloblastoma, have a poor prog-
nosis [12]. However, when adjuvant chemotherapy including
lomustine, cisplatinum, and vincristine is applied following
radiotherapy, the rate of relapse is reduced from 100% to
11.1% [12]. Other clinical findings show that when taken
individually, lomustine, vincristine, cisplatin, and cyclophos-
phamide confer the most beneficial survival effects over
craniospinal radiotherapy alone [13]. Similarly, lomustine
(and procarbazine) was shown to have marked inhibition of
neuroectodermal tumor, ependymomas, medulloblastoma,
and astrocytic gliomas in another study [14]. These studies
encourage and support the consideration and design of anti-
neoplastic agents that are structural analogs of lomustine, but
also for comparison to established guidelines of molecular
properties determined to be clearly efficacious for penetrating
through the BBB and entering the central nervous system.
Computational in silico methods are widely applied to
pharmacology hypothesis development and testing [15]. In
silico methods are frequently applied in the discovery and
optimization of novel molecules that have exclusive affinity
for a particular target. In addition, in silico methods are
used for elucidation of absorption, distribution, metabolism,
excretion, and toxicity properties of proposed medicaments
as well as the determination of physicochemical properties
[15].
Therefore, clinical studies clearly reveal the need for novel
antitumor agents that have effective antineoplastic activity
but withmolecular properties enabling the penetration of the
CNS. Although difficulties of CNS penetration are substantial
due to the BBB, design of molecular structures that effectuate
CNS infiltration is vital for treatment of brain tumors.
2. Materials and Methods
2.1. Molecular Modeling. Visualization and modeling of 2-
dimensional and 3-dimensional structures were accom-
plished by ACD Chem Sketch modeling v.10.00 (Advanced
Chemistry Development, 110 Yonge Street, Toronto, ON,
Canada M5C1T4). Various properties such as polar sur-
face area, violations of Rule of 5, molecular volume, num-
ber of oxygens, nitrogens, amines, and hydroxyls were
determined using Molinspiration (Molinspiration Chemin-
formatics, Nova ulica 61, SK-900 26 Slovensky Grob,
Slovak Republic). In silico structure search for substitu-
ent replacement was accomplished using chemical substr-
ucture and similarity search with Molinspiration Molec-
ular Database-Substructure and Similarity Search (http://
www.molinspiration.com/services/search.html).
2.2. Pattern Recognition Techniques. To identify underlying
associations and patterns within the multivariate data set
required the use of various pattern recognition techniques.
Included in the analysis is hierarchical cluster analysis
accomplished by KyPlot v. 2.0 Beta 15 (copyright Koichi
Yoshioka 1997–2001). Analysis of similarity (ANOSIM) is
accomplished by PAST v. 2.04 (copyright Oyvind Hammer,
D.A.T. Harper 1999–2008). Path analysis was accomplished
utilizing OpenStat numerical analysis (copyright W. Miller
November 20, 2010).
2.3. Numerical Analysis. Summary statistical analysis of
molecular properties of numerical data including correlation
analysis for Pearson 𝑟 was performed by Microsoft EXCEL
(EXCEL 2003, copyright 1985–2003). Multiple regression
analysis of molecular properties was accomplished by Graph
Pad Instat v. 3.00 for Windows 95 (Graph Pad Software,
San Diego, CA, USA). Grubbs’ test, also called the ESD
method (extreme studentized deviate), to determine whether
the most extreme value in the list entered is a significant
outlier from the rest (whether that one value is an outlier)
was determined by GraphPad online Software (GraphPad
Software Inc. 2236 Avenida de la Playa, La Jolla, CA 92037,
USA; http://www.graphpad.com/quickcalcs/grubbs2/).
3. Results and Discussion
Numerous studies have demonstrated that rigorous criteria
of molecular properties strongly correlate with and define
medicaments that penetrate through the BBB and into the
CNS. Outcomes of such studies report criteria for effective
CNS penetration by medicaments having polar surface area
(PSA) of 90Angstroms2 or less and formula weight cutoff
of 450 [16]. Additional studies encompassed other molecular
properties to expand the criteria. Contemporary studies
indicate that penetration into the CNS is most likely if the
following criteria exist [17]: (1) the formula weight is less than
or equal to 400; (2) Log 𝑃 is less than or equal to 5; (3)
hydrogen bond donors (–NH
𝑛
and –OH) less than or equal
to 3; and (4) hydrogen bond acceptors (oxygen and nitrogen)
less than or equal to 7. All 17 of the novel drugs proposed
here meet or exceed these necessary criteria for penetration
through the BBB.
Presented here are 17 novel drug designs elucidated by in
silico search by way of substituent similarity and substitution
utilizing lomustine as the parent structure. Accomplished
throughMolinspiration data base library,these 17 agents were
recognized from a total of more than 200 generated struc-
tures, thus having a success outcome of less than 10%. The 17
novel compounds identified (agents 2 to 18) are presented in
Figure 1 for a comparison with the parent compound which
is lomustine (agent 1).
Notable structural characteristics must include the
alkylating and cytotoxic nitrosourea moiety (O=C(NHR–)
N(N=O)CH
2
CH
2
Cl), with (–R) defined as the substituent
providing the variation of molecular properties (e.g., Log𝑃,
PSA, formula weight, etc.) but constrained to enhance
penetration into the CNS.
The (–R) substituent for lomustine is the nonaromatic
ring C
6
H
12
. A wide variety of structural substituents include:
halogens (agents 6 and 13), aliphatic carbon chains (14,3),
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Figure 1: Seventeen novel nitrosourea anticancer structures (2 to 18) obtained from substructure and similarity search analysis applying
lomustine as parent structure are presented for comparison. The structures are substantially diverse by substituent following the nitroso (R–
NO) and urea group OC(NH
𝑛
)
2
. Other notable substituent aspects include aliphatic carbon chains, double-bond carbon chains, hydroxyl
(–OH) groups, halogens (Cl and Br), and ring structures.
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Table 1: Molecular properties of anticancer agents.
Drug Log P Polar surface area
(Angstroms2)
Number of
atoms
Molecular
weight
Number of
O & N
Number of –OH
and –NH
𝑛
Violations
of Rule of
5
Number of
rotatable bonds
Volume
(Angstroms3)
1 2.965 61.772 15 233.7 5 1 0 4 208.8
2 2.188 61.771 12 191.6 5 1 0 4 163.1
3 2.268 61.771 13 207.7 5 1 0 5 185.5
4 2.034 61.771 13 205.6 5 1 0 5 179.9
5 2.457 61.771 13 203.6 5 1 0 5 174.2
6 2.583 61.771 16 268.1 5 1 0 4 222.3
7 1.975 61.771 13 205.6 5 1 0 6 180.1
8 2.276 61.771 16 251.7 5 1 0 4 213.7
9 2.429 61.771 14 217.7 5 1 0 5 190.5
10 2.359 61.771 14 219.7 5 1 0 5 196.1
11 2.476 61.771 16 267.8 5 1 0 8 236.9
12 1.537 81.999 15 237.7 6 2 0 6 210.4
13 3.184 61.771 16 312.6 5 1 0 4 226.7
14 2.498 61.771 13 207.7 5 1 0 6 185.7
15 2.635 61.771 15 231.7 5 1 0 6 206.9
16 3.924 61.771 17 261.7 5 1 0 8 246.5
17 3.182 61.771 16 245.7 5 1 0 6 223.5
18 2.459 61.771 14 219.7 5 1 0 4 191.9
Table 2: Property statistics.
Property Mean Minimum Maximum Median Standard deviation
Log P 2.524 1.537 3.924 2.458 0.5337
Polar surface area (A2) 62.89 61.77 82.0 61.77 4.768
Number of atoms 14.5 12 17 14.5 1.465
Molecular weight 232.8 191.6 312.6 225.7 30.76
Number of O & N 5 5 6 5 0.2357
Number of –OH and –NH
𝑛
1 1 2 1 0.2357
Violations of Rule of 5 0 0 0 0 0
Number of rotatable bonds 2.3 4 8 5 1.274
Volume (A3) 202.4 163.1 246.5 201.5 23.03
alkene carbon chains (17, 16, 15, 7, 5, 10, 4), hydroxyl groups
–OH (14), carbon rings (8, 13, and 18), and a sulfanylidene
group (11). The marked variation in the (–R) substituent is
shown to enable a beneficial variation inmolecular properties
of vital significance to effectuate drug penetration into the
CNS.
Pharmacological properties of agents 1 to 18 are compiled
in Table 1. Careful statistical analysis of numerical values is
shown inTable 2 for consideration of library search efficiency.
Notably the mean Log𝑃 is 2.524 (standard deviation (SD) =
0.5337) with range of 1.537 to 3.924: formula weight (FW)
mean of 232.8 and range of 191.6 to 312.6. The range for
number of hydrogen bond acceptors oxygen and nitrogen
atoms (O & N) is tight from 5 to 6, mean of 5. Likewise the
range for hydrogen bond donors hydroxyl (–OH) and amines
(–OH & –NH
𝑛
) is only 1 to 2 with mean of 1. These four
properties are selected outright to emphasize that the search
outcome adheres very well with the CNS penetrating criteria
stated previously to wit [17]: (1) FW ≤ 400; (2) Log𝑃 ≤ 5;
(3) –OH &–NH
𝑛
≤ 3; (4) O & N ≤ 7. Similarly, another
criterion of PSA ≤ 90Angstroms2 and FW ≤ 450 [16] is
well satisfied for BBB penetration, from numerical values
in Table 1. Clearly the in silico library search for similarity
and substituent substitution can be highly accurate; even the
criteria are highly precise in demand. Formula weight was
highly correlated (Pearson 𝑟 > 0.8700) to number of atoms,
and molecular volume was highly correlated to number of
atoms and formula weight (𝑟 > 0.8700). The number of
atoms, molecular volume, and formula weight is moderately
correlated to Log𝑃 (Pearson 𝑟 > 0.5000). There are no
outliers (two-sided 𝑃 = 0.05) among numerical values of
Log𝑃, formula weight, and molecular volume.
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Figure 2: Result of hierarchical cluster analysis (Euclidean distance,
single linkage) presented as vertical dendrogram and divisive anal-
ysis is presented. The initial supercluster is separated into a unique
distinction of agent 12 at node A, followed with others 16, 11, 13, 6,
and 8 at node B, finally including lomustine (1) at node C.
Multivariate statistics is a form of statistics encompassing
the simultaneous observation and analysis of more than one
outcome variable (see Table 1) [18].
The purpose of cluster analysis is to discover a system of
organizing objects into groups (or clusters) where members
within the groups share properties in common suggested
by the data itself (i.e., not known a priori), and objects
in different clusters tend to be dissimilar [18]. Hierarchical
cluster analysis of the multivariate Table 1 produced the
vertical divisive dendrogram presented in Figure 2 for visu-
alization of the relative resemblance to the parent compound
lomustine (agent 1). Conditions are standard Euclidean
distance (the geometric distance in the multidimensional
space) and single linkage (the distance between two clusters
is determined by the distance of the two closest objects)
[18]. The analysis clearly distinguishes agent 12, at node A
(containing a hydroxyl group –OH), from all the remaining
agents. Essentially all remaining agents fall under node B, but
includes some finer elucidation of agents 16, 11, 13, 6, and 8
from the remainder under node C. Other than agent 12, the
finer closest similarity of lomustine is to agents 2, 3, 4, 5, 7, 9,
10, 18, 14, 15, and 17.
Additional advantage of these nitrosourea agents is prop-
erties that affirm effective oral administration. Oral activity is
a desirable druglikeness character that is identified through
zero violations of the Rule of 5 [19]. The rule states that, in
general, an orally active drug has no more than one violation
of the following criteria: (1) not more than 5 hydrogen bond
donors (nitrogen or oxygen atomswith one ormore hydrogen
atoms); (2) not more than 10 hydrogen bond acceptors
(nitrogen or oxygen atoms); (3) a molecular mass less than
500 daltons; and (4) an octanol-water partition coefficient
Log𝑃 not greater than 5.
Previous studies have shown that PSA and Log𝑃 can be
used to estimate the quantitative transfer of a neurological
drug from the blood into the CNS.
Table 3: Log BB and BB values.
Agent Log BB BB
1, lomustine −0.325 0.473
2 −0.443 0.361
3 −0.430 0.372
4 −0.466 0.342
5 −0.402 0.396
6 −0.383 0.414
7 −0.475 0.335
8 −0.429 0.372
9 −0.406 0.393
10 −0.416 0.383
11 −0.399 0.399
12 −0.841 0.144
13 −0.291 0.512
14 −0.396 0.402
15 −0.375 0.422
16 −0.179 0.662
17 −0.292 0.511
18 −0.401 0.397
The ratio of drug concentration in the brain to concen-
tration in the blood can be represented as 𝐶brain/𝐶blood or
BB. The expression utilizing PSA and Log𝑃 to accurately
determine Log BB [20] is shown in
Log BB = −0.0148 (PSA) + 0.152 (Log𝑃) + 0.139. (1)
For agents 1 to 18, the values of Log BB and BB are shown in
Table 3.
The average value of BB (or 𝐶brain/𝐶blood) is 0.405
(standard deviation = ± 0.102) with minimum of 0.144 and
maximum of 0.662. The average value of Log BB is −0.108
compared to Log BB of lomustine at −0.325. These results
indicate that a significant amount of each agent will cross into
the CNS. No outlier was found among numerical values of BB
(two-sided 𝑃 = 0.05).
The purpose of multiple regression is prediction of a
dependent variable based on multiple independent variables
[18] or molecular properties for drug prediction. Multiple
regression analysis of descriptors in Table 1 to forecast for-
mula weight (FW) of similar compounds based on Log𝑃,
PSA, number of rotatable bonds (nRot), and number of atoms
(Atoms) the following equation (2) accounts for 79.34% of the
variance in formula weight (𝑅2 = 0.7934):
FW = −24.859 + 0.9578 (Log𝑃) − 0.04598 (PSA)
+ 19.236 (Atoms) − 3.947 (nRot) .
(2)
ANOSIM (Analysis of Similarity) is a nonparametric
(randomization-based) method of multivariate analysis that
is widely used. It is used mainly to compare the variation of
object abundances and composition among sampling units
[21].
ANOSIM result for Table 1 multivariate array is 𝑅 =
1.000, which suggests a diverse distribution of numerical
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Table 4: Path analysis causal effect on formula weight.
Property Path coefficient
Log P −0.085
Polar surface area −0.027
Number of atoms 0.449
Number of oxygens and nitrogens −0.027
Number of –OH and –NH
𝑛
−0.026
Number of rotatable bonds 0.499
Molecular volume 0.005
values within these properties and a characteristic of the
in silico search result. ANOSIM results reaffirm the diverse
nature of the structure-based substituent substitution with
differences of atoms and their effect on molecular properties.
Path analysis is a straightforward extension of multiple
regression analysis also for prediction. The aim is to provide
estimates of the magnitude and significance of hypothe-
sized causal connections among sets of variables [21]. Path
coefficients are standardized weights which can be used in
examining the possible causal linkage between variables. A
path coefficient shows the direct effect of an independent
variable on a dependent variable in the path model [21].
Path coefficients for causal relationship of various prop-
erties to formula weight are shown in Table 4. The greater
the positive value of the path coefficient, the stronger the
causal relationship. Clearly the number of atoms (coefficient
= 0.449) and number of rotatable bonds (coefficient = 0.499)
have a level of moderate to strong causality for formula
weight, Unlike Log𝑃, PSA, molecular volume, number of
–OH and –NH
𝑛
, and number of O and N atoms that have
coefficient values less than 0.100.
In silico pharmaceuticalmodeling is ongoing anddemon-
strates plentiful array of possibilities in expediting the discov-
ery of new targets and discerning lead compounds that have
predicted biological activity for these novel targets [15].
In silico methods include databases, quantitative stru-
cture-activity relationships, similarity searching, pharma-
cophores, homology models, molecular modeling, machine
learning, data mining, network analysis tools, and computa-
tion of based data analysis tools [15]. The cultivation of brain
tumor biopsies has been achieved [22], and the testing of
these nitrosourea agents and other similar anticancer drugs
could be evaluated for effectiveness by in vitro methods.
4. Conclusions
In silico substructure search produced 17 novel nitrosourea
agents that are analogous to lomustine and retain the DNA
alkylating component required for cytotoxic activity. The 17
new designs were derived from a data library search netting
over 200 hits but only the structures presented here have
molecular properties suitable for penetration through the
BBB and into theCNS.This is a success rate of less than 10%of
all search excerpts. All compounds have a polar surface area
of less than 90Angstroms2 and Log𝑃 values of less than 5.
Prediction of drug passage into the CNS can be quan-
titatively estimated using relationships of PSA and Log𝑃
from studies of current neurological drugs. For these 18
nitrosoureas, themean values of LogBB andBB are−4.08 and
0.405, respectively. No outlier was found among values of BB
(two-sided 𝑃 = 0.05).
The range in BB values extended from 0.144 to 0.662,
showing that estimated levels of CNS penetration are signifi-
cant for all structures.
The use of in silico methods is a potent and promising
addition to other approaches to drug candidate elucidation.
The database generated 17 nitrosourea agents having zero
violations of the Rule of 5 as well as molecular properties
known to enable and enhance penetration of the CNS. This
study shows that a contemporary algorithm for searching
molecular libraries is able to identify structures suitable for
further examination. The molecular properties necessary for
effective neurological activity are sufficiently elucidated for
identifying potential candidates that fall within the rigid
criteria for clinical application.
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